|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2001-12-0241.
NEOPLASIA
From Centre Hospitalier Universitaire (CHU), Toulouse, France;
Institut Paoli Calmettes, and CHU, Marseille, France; Hôpital
Debrousse, Lyon, France; Hôpital Necker, Hôpital
Bicêtre, Hôpital Saint Antoine, Hôpital Robert
Debré, and Hôpital Saint Louis, Paris, France; Centre Henri
Becquerel, Rouen, France; CHU, Nantes, France; Hôpital Haut
Lévêque, Bordeaux, France; Hôpital Universitaire,
Genève, Suisse; CHU, Reims, France; CHU, Brest, France; CHU,
Dijon, France; CHU, Montpellier, France.
To draw the cytogenetic profile of childhood and adult acute
megakaryoblastic leukemia (M7), the Groupe Français de
Cytogénétique Hématologique collected 53 cases of M7
(30 children and 23 adults). Compared to other acute myeloid leukemias,
M7 is characterized by a higher incidence of abnormalities, a higher
complexity of karyotypes, and a different distribution of abnormalities
among children and adults. Nine cytogenetic groups were identified: normal karyotypes (group 1), patients with Down syndrome (group 2),
numerical abnormalities only (group 3), t(1;22)(p13;q13) or OTT-MAL transcript (group 4), t(9;22)(q34;q11) (group 5),
3q21q26 (group 6), Few large series of acute megakaryoblastic
leukemias, M7 according to the French-American-British (FAB)
classification,1 have been reported, some having included
only children2,3 and others mainly adults.4-6
The only study comprising both childhood and adult M7 was that reported
by Lu et al who reviewed all cases with documented cytogenetic data
published before 1993.7 These previous studies revealed
evidence for cytogenetic heterogeneity among cases with acute
megakaryoblastic leukemia. In children, at least 2 entities have been
recognized, M7 developing in patients with Down syndrome (DS) and M7
associated with t(1;22)(p13;q13) in early infancy. Strong associations
have not been found among adults who are characterized by a larger
diversity of chromosomal abnormalities including 3q21q26 changes,
aberrations of chromosomes 5 and 7, and t(9;22)(q34;q11). However, the
distribution of cytogenetic abnormalities in childhood and adult M7 has
not been reported to date.
M7, the most frequent type of acute myeloid leukemia (AML)
occurring in DS patients, is characterized in these young patients by
unique features (for a review, see Lange8). It is often preceded by a transient myeloproliferative phase, is commonly associated with a concurrent involvement of erythroid precursors, and
shows a remarkable responsiveness to AML therapy. The occurrence of
t(1;22)(p13;q13) is restricted to acute megakaryoblastic leukemia and infancy.9,10 This translocation has seldom been
detected in children older than 1 year and occasionally in DS
patients.11,12 The genes implicated in 1p13 and 22q13 have
recently been identified.13,14 The OTT
(RBM15) gene located on 1p13 is fused to the MAL
(MLK1) gene on chromosome 22 leading to the
OTT-MAL (RBM15-MLK1) fusion gene on the
derivative 22. The outcome of these patients is usually poor, but
long-term survivors after intensive therapy have been reported.9,10 Other than poor prognosis, no specific
features have been associated with M7 occurring in children without DS or t(1;22).3 Likewise, the outcome of adulthood M7 is
extremely poor and has been primarily attributable to resistant
disease.6 No specific association between outcome and
chromosomal abnormalities has been established in this age group.
The aim of our study was to collect a significant number of
megakaryoblastic leukemias with successful karyotype, to draw the
cytogenetic profile of this rare myeloid malignancy. A morphologic review of all cases recorded was simultaneously undertaken by the
Groupe Français d'Hématologie Cellulaire (GFHC) to ensure that megakaryoblasts were the sole or the major component of the malignant proliferation. Therefore, because of strict morphologic and
immunophenotyping criteria used to validate an M7 diagnosis, we can
expect that our study would reflect the cytogenetic features of
megakaryoblastic proliferations among children and adults.
A retrospective study of M7 leukemias (1988-1999) was carried
out by the Groupe Français de Cytogénétique
Hématologique (GFCH). The criteria required to include a case
were both a successful karyotype reviewed by the GFCH and a validation
of the morphologic and immunophenotyping data by the GFHC (chaired by 2 morphologists O.F. and E.D.).
Morphologic and immunophenotypic validation
Cytogenetics
Fluorescence in situ hybridization studies Fluorescence in situ hybridization (FISH) analyses were performed with commercially available probes according to the manufacturer's instructions and methods previously described.18 Whole chromosome painting (wcp) was carried out in case 22 with chromosomes 1, 14, and 22 wcp; in case 23 with chromosomes 1 and 22 wcp; in case 42 with chromosomes 4, 5, 7, and 13 wcp; and in case 49 with chromosomes X, 7, and 22 wcp. In case 43, i(12)(p10) was studied using ETV6/TEL 50F4 cosmid concurrently with a centromeric probe of chromosome 12 (D12Z3) and in case 46, t(16;16) was analyzed by painting the short arm of chromosome 16 (Appligene Oncor, Gaithersburg, MD). Case 50 (21q21 breakpoint) was studied with an AML1 probe (LSI TEL-AML1 ES; Vysis, Downers Grove, IL) and cases 48 and 51 (16p12 and 16q21 breakpoints) with a CBF probe (LSI CBFB dual color; Vysis).
Reverse transcription-polymerase chain reaction analyses In patients with a t(16;16)(p13;q22) and a t(16;21)(p11;q22) (cases 45 and 46), the CBF-MYH11 and the
TLS/FUS-ERG fusion transcripts were studied according to
described methods.19,20 Reverse transcription-polymerase
chain reaction (RT-PCR) for detection of an OTT-MAL
transcript using primers recently described21 was
performed in infants without t(1;22) or DS (cases 1, 10, 13) and in one
of the variant t(1;22) (case 23).
Statistical analyses The numbers of patients with a given feature were compared using the 2 test. Achievement of complete remission (CR) was
assessed for the 26 children and the 16 adults who received therapy.
Probabilities of event-free survival (EFS) and of survival were
evaluated using the log-rank test.22
Patients This retrospective study included 30 children and 23 adults from 1 Swiss and 15 French centers (see list of participants in "Appendix").Clinical and hematologic data A bimodal age distribution was observed with 2 peaks of frequency, M7 occurring in infancy and among the elderly. All children (except one 7-year-old patient) were younger than 3 (median age, 1 year; range, 0-7 years), and 43% of them were infants (< 1 year). Six were congenital leukemias (below 1 month). The median age of adults was 58 years (range, 19-79 years).In 90.5% of patients, M7 was diagnosed as a de novo leukemia. In 3 adults, M7 occurred after a hematologic disorder: one chronic myeloid leukemia (case 24), one myelodysplastic syndrome (case 36), and one essential thrombocytemia (case 27); this latter patient also received hydroxyurea for several years. M7 might be secondary to a previous toxic exposure in 2 further cases: a patient with lymphoma treated with an intensive chemotherapy regimen (case 32), and a patient with breast cancer who underwent radiotherapy (case 34). Hepatosplenomegaly was mostly found in children; splenomegaly was present in 70% of children and 26% of adults, whereas hepatomegaly was observed in 60% and 35%, respectively. Lymph node enlargement was rare in children (11%) and never observed in adults. Periostosis contributed to clinical diagnosis in 4 children. Other sites of disease included mediastinal mass (the 2 adults of group 8), kidney involvement (2 infants), chloroma (1 infant), and central nervous system (1 infant). Children were treated according to either the European Organization for Research and Treatment of Cancer-Children Leukemia Cooperative Study Group 58872 (EORTC-CLCG58872)23 or the Leucémie Aigue Myéloblastique de l'Enfant 89/91 (LAME89/91) trials,24 except patients with DS who received low-dose cytarabine in 6 of 7 cases (the patient with congenital disease died at birth). The Bordeaux Grenoble Marseille Toulouse (BGMT87), BGMT91, or BGMT95 protocols25 were administered to the 16 adult patients who completed therapy. Children fared better than adults, achieving CR more easily (CR: 77% in children versus 33% in adults; P < .01) and having longer survivals (3-year survival probability, 36%; 95% CI, 20-56; median survival, 16 months) than adults (3-year survival probability, 0%; 95% CI, 2-24; median survival, 4 months; P < .01). All adults had a poor outcome, whereas among children, outcome differed according to karyotype. The longest survivals were observed in patients with DS (3-year EFS, 57%; 95% CI, 20-88; 3-year survival, 71%; 95% CI, 30-95). Patients with t(1;22) either died within a few days (before starting therapy in 3 cases) or were good responders to intensive therapies (chemotherapy alone or associated with allogeneic bone marrow transplantation [BMT] or autologous BMT). Their 3-year EFS probability was 50% (95% CI, 20-80). Outcome was poor in all children without DS or t(1;22) (3-year EFS, 8%; 95% CI: 0-38). Peripheral white blood cell (WBC) counts were more elevated in children (median WBC count, 14.4 × 109/L) than in adults (median WBC count, 4.6 × 109/L; P < .05), whereas hemoglobin and platelet counts were low in both age groups. Bone marrow biopsy showed reticulin myelofibrosis in 9 of 13 documented cases. The GFHC classified M7 into 3 morphologic categories according to the
degree of maturation displayed by blasts. In the first category,
megakaryocytic lineage involvement was unequivocally evoked by
morphologic features of the nuclei and cytoplasm. Category 1 was then
subdivided into 2 subgroups (1A and 1B) according to blast size,
chromatin density, and cytoplasm abundance and shape. Category 2 was
characterized by coexistence of blasts with typical megakaryocytic
attributes (as in category 1) with a population of undifferentiated
blasts. Category 3 was composed solely of morphologically
undifferentiated blasts. In all cases, the presence of abnormal
megakaryocytic maturation, mainly characterized by the presence of
micromegakaryocytes, was also assessed. Micromegakaryocytes, quoted as
"m" in the morphologic classification were only observed in
categories 1 and 2 (Table
1).
Several cases submitted were rejected by the morphoimmunologic validation procedure. The most frequent reason for rejection was mixed leukemias with a major component of myeloblasts in addition to megakaryoblasts. However, 6 patients with mixed proliferations were kept: 3 with a minor proerythroblastic (cases 5, 9, 47) and 3 with a minor myeloblastic component of blasts (< 10% of blasts; cases 26, 43, 45). The GFHC also assessed cases for myelodysplastic features of the erythroid and granulocytic lineages when the number of residual cells allowed this evaluation. Dysgranulopoiesis was never observed among children and was present in 35% of adults. Dyserythropoiesis was found in 23% of children and in 22% of adults. Only one adult (case 40) presented with features of trilineage dysplasia. Cytogenetic data Constitutional karyotype was checked in 11 cases and the only constitutional chromosomal abnormality found was trisomy 21. One of the patients with DS also had a constitutional translocation (case 5). In one case of DS with trisomy 21 in mosaicism (case 8), the acquired clonal aberrations occurred in the clone +21c. Constitutional karyotype was normal in 2 patients with an acquired trisomy 21 (cases 10 and 11).In 3 patients, including one with DS, no acquired abnormality was present. These karyotypes were classified as normal (NN). Clonal changes were observed in 94% karyotypes, either with normal cells (AN in 34 patients) or without (AA in 16 patients). Distribution of the ploidy groups showed that karyotypes were mostly pseudodiploid (60% in children and 43% in adults). Hyperdiploidy was present in 26% of children and 35% of adults. In the hyperdiploid group, modal numbers ranged from 47 to 54 with a clear predominance of 47 and 48 modal numbers in children and in adults. Triploidy and tetraploidy were rare (3 cases) and only found in adults. Hypodiploidy was more common in adults (22%) than in children (only one case). Complexity was assessed according to the number of unrelated
abnormalities ( Most of the karyotypes (70%) were composed of unbalanced abnormalities, either with numerical (6 cases) or with both numerical and structural changes (44 cases). Chromosome gains and losses are shown in Figures
1 and 2.
Gains involved mainly chromosomes 8, 19, and 21, and partial trisomy 1q. Chromosomes implicated in losses were chromosomes 5, 6, 7, 9, 11, 13, 16, and 17. For chromosomes 5 and 7, partial deletions of the long
arm were more frequent than losses of the whole chromosome. Five
partial deletions of the short arm of chromosome 17 and 5 deletions of
the long arm of chromosome 6 were observed.
Abnormalities found as sole changes were either balanced: t(X;16)(q28;p12), t(1;22)(p13;q13), t(9;22)(q34;q11), t(3;12)(q26;p13), t(16;16)(p13;q22), t(16;21)(p11;q22), inv(3)(q21q26) or unbalanced: +3,+21, der(1;7)(q10;p10), del(7)(q31q35), del(5)(q23q33), add(13)(q33), del(13)(q13q32) (Table 1). All the breakpoints are shown in the diagram of Figure
3. The chromosomal regions most often
disrupted were 5q (n = 18), 22q (n = 16), 7q (n = 14), 1p
(n = 11), 3q (n = 9), 6q (n = 8), 11q (n = 8), and 9q
(n = 7). The breaks in 1p, 22q, and 9q mostly resulted from
t(9;22)(q34;q11) and t(1;22)(p13;q13). The breaks delineating the
deletions accounted for the frequent involvement of 5q, 7q, and 6q.
However, other clusters of breaks not involved in these known changes
were also identified. A possible hot spot was 17q22-23 involved in 5 translocations, t(5;17)(p13;q22), t(16;17)(q21;q22), t(11;17)(p15;q23), t(7;17)(q22;q23), and a deletion,
del(17)(q22). The 11q14-22 bands were implicated in 4 cases: 3 translocations, t(11;21)(q14;q22), t(4;11)(q28;q22), add(11)(q22)
and a deletion del(11)(q22q24). Another cluster of breaks
was observed in 21q21-22 rearranged in 4 translocations:
t(X;21)(q24;q21), t(16;21)(p11;q22), t(11;21)(q14;q22),
t(14;21)(q24;q22). The long arm of chromosome 16 was implicated in 3 changes involving the region 16q21-22-23: t(16;17)(q21;q22),
t(16;16)(p13;q22), and add(16)(q23).
Karyotypes were then classified according to the presence of a recurrent change. In this classification, the DS were kept together as a group whatever their acquired changes. When 2 recurrent changes were observed, the most probable primary change determined the inclusion in a given group. Nine groups were identified (Table 1). FISH and molecular results No rearrangements of AML1 (case 50) and CBF (cases 48 and 51) genes were detected with FISH
analyses. In cases 48 and 51, these results allowed us to rule out a
cryptic inv(16)(p13q22).
In cases 1 and 10, no OTT-MAL fusion transcript was found. However, in case 13 with a normal karyotype, a strongly expressed OTT-MAL transcript was detected. No material was available to check the presence of the fusion gene with FISH. The t(1;22;4) also showed an OTT-MAL transcript (case previously reported by Mercher et al13) In case 46, FISH analysis confirmed the t(16;16)(p13;q22) and RT-PCR
detected a G-type CBF Lack of correlation between the cytogenetic groups and the morphologic classification No relationship could be established between the cytogenetic and the morphologic features because all morphologic aspects (categories 1, 2, and 3) were observed in each cytogenetic group (Table 1). The 3 morphologic categories were evenly distributed in the 2 age cohorts except for category 3, which was only found among adults.Characteristics of the 9 cytogenetic groups Group 1 (normal karyotypes) initially included 2 infants. However, one of them (case 13) showed an OTT-MAL fusion transcript and was therefore included in the t(1;22)(p13;q13) group (group 4). The only infant in group 1 had a relapse early after allogeneic BMT.Group 2 (DS) had a median age of 2 years and low leukocytoses (median,
5 × 109/L) and platelet counts (median,
20 × 109/L). No preceding transient myeloproliferative
phases or myelodysplastic syndromes were observed and 2 patients had a
minor population of proerythroblasts. This group had a favorable
outcome (see "Clinical and hematologic data") because only
2 patients had relapses (cases 6 and 8). Case 8 with a complex
karyotype died in relapse, whereas case 6 achieved second CR. Prognosis
was not impaired by the presence of Group 3 (numerical abnormalities not associated with structural changes) contained only trisomies. No OTT-MAL transcript was detected in the infant (case 10) analyzed by RT-PCR. Prognosis was poor in all cases. Group 4, made up of patients with t(1;22) or with an OTT-MAL transcript, showed a prevalence of infant and congenital leukemias, female preponderance, and propensity to hepatosplenomegaly. Morphologically, the unifying feature of these patients was the constant presence of micromegakaryocytes in addition to blasts. In the 2 variant translocations identified, t(1;22;4)(p13;q13;q35) and t(1;22;14)(p13;q13;q31), the derivative 22 was of identical appearance to cases with the classical t(1;22) and the derivative 1 displayed the translocated portions of chromosomes 4 and 14. This group experienced an intermediate outcome and some patients proved to be good responders to intensive therapy (see "Clinical and hematologic data"). The Philadelphia (Ph) chromosomes included in group 5 were found in
both de novo M7 (cases 25 and 26) and a blastic phase of chronic
myeloid leukemia (CML) (case 24). A fourth t(9;22) (case 28), found as
a secondary change, was included in group 6. Outcome was poor for all
patients but survivals were shorter when Ph chromosome was associated
with inv(3) or Group 6, 3q21q26, was made up of patients with only 3q21 (cases 31, 32), only 3q26 (case 27), or both 3q21 and 3q26 (cases 28, 29, 30) breakpoints. Micromegakaryocytes were observed in only 2 patients and platelet counts were low except in case 28, which had a normal platelet count. Complete or partial deletions of chromosomes 5 and 7 were frequently associated and prognosis of this 3q21q26 group was very poor (median survival, 4.8 months) although the 2 children experienced longer survivals (21 and 23 months). Group 7, composed of The patients of group 8, characterized by an isochromosome 12p, were
young adults with a mediastinal mass and elevated serum markers
( Among the miscellaneous changes found in group 9 there were recurrent
and rare abnormalities. One of the recurrent changes was a
t(16;16)(p13;q22) with a CBF
The 53 cases of M7 collected in the current study allowed us to describe the spectrum of cytogenetic abnormalities found in this malignancy with their respective frequencies among children and adults, to analyze the features characterizing the main cytogenetic groups and to make assumptions on the origin of this acute leukemia (either de novo or secondary) and on the possible precursors involved. To describe the cytogenetic features of M7, frequencies of the different cytogenetic abnormalities were compared with those of large series of de novo and secondary AMLs, which have included all FAB types from M1 to M7. We could establish these comparisons because our series was only composed of M7, whereas M7 represented less than 5% of cases in large published series of AML. This approach enabled us to better define the similarities and the discrepancies of M7 as compared to other acute myeloid proliferations and to specify the incidence of different changes in children and adult M7. The high percentage of abnormal karyotypes (94%) found in our series showed that the percentage of abnormal karyotypes is higher in M7 than in de novo AMLs in which abnormal karyotypes represent approximately 80% of cases in children26-28 and 50% to 60% of cases in adults.29,30 In our study, karyotypes were complex in 39% of children and 52.5% of adults with a higher degree of complexity in adults than in children. These findings show that there are more complex karyotypes in M7 than in de novo AMLs in which the complex karyotypes represent 10% of cases in pediatric series31 and 34% of cases in adults (> 55 years).29 M7 presented similarities with other AMLs. The distribution of the
ploidy groups and the cytogenetic profile of chromosome gains and
losses were comparable to those observed in de novo AML, as exemplified
by the most frequent trisomies (+8,+19,+21) and monosomies ( Other features uncommonly found in de novo AMLs, characterized our M7 series: partial trisomies for the long arm of chromosome 1, partial deletion of chromosome 6q, trisomy 6, and deletion of chromosome 9 and of chromosome 11 (complete or involving 11q). Trisomy 6 was found in 6% of cases in Lu et al's series.7 No new recurrent abnormality was identified and the diversity of changes observed in our study illustrated the cytogenetic heterogeneity of M7. By classifying karyotypes according to the most probable recurrent abnormalities, we described 9 cytogenetic groups that probably comprised diseases presenting an M7 morphology. These groups were differently distributed among young and old patients. In our study, t(1;22) was the most frequent abnormality among children
(33%). This frequency was higher than in the Lu et al7
(20%) and Athale et al3 (2.5%) studies, but it was in agreement with previous reports estimating that t(1;22) represents approximately one third of childhood M7.9,26,27 The
finding of an OTT-MAL transcript in a patient with a normal
karyotype suggests that the frequency of this group is still probably
underestimated. The t(1;22) might be cryptic but it might also be
undetected because it is often present in minor clones as attested by
the frequently low numbers of blasts and of abnormal metaphases in
these patients. The percentage of DS among our young patients (23%) is
more in agreement with the frequency reported by Ribeiro et
al2 (21%) and Athale et al3 (15%) than with
that reported by Lu et al7 (54% of the children). In our
study, 43% of children (13 patients) presented with normal karyotypes
(2 patients), simple numerical changes (3 patients), complex karyotypes
including 3q, 5q Among adults, group 7, Most of the features characterizing the 9 cytogenetic groups were in
agreement with previous studies. However, some divergent or new
specific data need to be emphasized. In patients with DS, we did not
observe either the frequently reported transient myeloproliferative phase, or the trisomy 1q and trisomy 8 in karyotypes. In patients with
t(1;22), the constant presence of micromegakaryocytes in addition to
low percentages of blasts appeared as a new specific feature of this
cytogenetic entity. These features were also observed in the patient
with a normal karyotype and an OTT-MAL fusion transcript. The cytogenetic presentation of the 2 complex variants suggested that
the derivative 22 is the critical chromosome. This assumption was
reinforced by the recent description of the OTT-MAL fusion located on the derivative 22.13 Only one other variant has
been previously reported.36 In group 6, 3q21q26, as
opposed to the dysmegakaryocytopoiesis and the high platelet counts
reported in myeloid malignancies with 3q
abnormalities,37,38 micromegakaryocytes were rarely
observed and platelet counts were low. The patients of group 8 (isochromosome 12p) presented with the features expected in the
syndrome associating a mediastinal germ cell tumor (MGCT) and a
hematologic malignancy (M7 in one third of cases).35 In addition to the typical clinical and biologic presentation, the near-triploid karyotypes displayed the chromosome gains and losses frequently observed in germ cell tumors, that is, the 2 patients shared
losses of chromosomes 4 and 9, whereas chromosome 13 was lost in one
patient and rearranged in the other. Coexistence of a triploid
karyotype with a mediastinal mass in young adults with M7 should lead
to a systematic search of i(12)(p10), which might be difficult to
identify in complex karyotypes. In group 9 (miscellaneous changes), we
observed a t(16;16)(p13;q22) with a CBF Primary changes of a tumor, strongly related to the development of malignant proliferation, are sole and balanced structural abnormalities in the vast majority of cases.41 In our series, among the single abnormalities, t(1;22) has closely been related to M7, whereas most of the others (see list in "Results") have been mainly related to other myeloproliferative, myelodysplastic malignancies or acute leukemias and occasionally published in M7. Conversely, the t(X;16)(q28;p12), which has not been previously reported, and trisomy 3, which is a very rare numerical change in AML, were both observed as sole abnormalities, thereby emerging as possible primary changes in M7. In addition to frequent breakpoints resulting from known recurrent changes, our study revealed several clusters of more uncommon breakpoint regions, located on 17q22-23, 11q14-21, 21q21-22, and 16q21-22-23. Because these breaks were mostly generated by rare translocations in simple karyotypes (not associated with changes previously related to M7), we can assume that they might pinpoint hot spots of rearrangements frequently involved in M7. Among the genes mapped in these regions, only CBFA2 (AML1) located in 21q22, has proved to be involved in megakaryopoiesis.42 No rearrangement of AML1 gene was detected in our study but only 1 of the 4 patients with a 21q21-22 breakpoint could be analyzed using molecular methods. Despite the absence of a suggestive history among 90.5% of patients in our series, several cytogenetic and morphologic features argued in favor of the occurrence of M7 as a secondary leukemia. In adults, this assumption was supported by the high incidence of
complex karyotypes, of unbalanced changes, of In contrast to adults, there was little evidence to suggest that
childhood M7 typically arises as a secondary leukemia, because no
dysgranulopoiesis and few of the "hallmark" chromosomal
abnormalities were observed. In contrast with a recent series of
childhood M7, which reported that 15% occurred after prior therapy for
acute lymphoblastic leukemia with a frequent involvement of
11q23,3 no prior toxic exposure was identified in the
children of our study and the only 11q23 breakpoint was found in one
patient who also presented with the classical combination of 3q, The morphologic and cytogenetic features also led us to hypothesize on
the precursors involved in M7. Although the megakaryocytic commitment
of blasts was unequivocal in all cases, the initial precursor involved
seemed to be more immature in adults than in children as evidenced by
the high frequency of 3q21q26, t(9;22), This study on 53 patients with acute megakaryoblastic leukemia validated by a review of morphologic and immunophenotyping data is the largest comprehensive series with cytogenetic data including children and adults reported to date. It allowed us to display the spectrum of recurrent changes observed in M7, to assess their frequencies and to emphasize the differences between M7 developing in infancy and adulthood. The diversity of chromosomal abnormalities and their frequent association in complex karyotypes account for the difficulty in understanding the primary molecular rearrangements.
We thank David Grimwade for his most valuable suggestions and Mariana Titorov for her editorial assistance.
Submitted December 13, 2001; accepted March 11, 2002.
Prepublished online as Blood First Edition Paper April 17, 2002; DOI 10.1182/blood-2001-12-0241.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nicole Dastugue, Laboratoire d'Hématologie, Génétique des Hémopathies, Hôpital Purpan, Place du Dr Baylac, 31059 Toulouse Cedex, France; e-mail: dastugue.n{at}chu-toulouse.fr.
1.
Bennet M, Catovsky D, Daniel M-T, et al.
Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7) : a report of the French-American-British Cooperative Group.
Ann Intern Med.
1985;103:460-462 2. Ribeiro R-C, Olivier M-S-P, Fairclough D, et al. Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases. Leuk Lymphoma. 1993;10:299-306[Medline] [Order article via Infotrieve].
3.
Athale U-M, Razzouk B-I, Raimondi S-C, et al.
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience.
Blood.
2001;97:3727-3732
4.
Cuneo A, Mecucci C, Kerim S, et al.
Multipotent stem cell involvement in megakaryoblastic leukemia: cytologic and cytogenetic evidence in 15 patients.
Blood.
1989;74:1781-1790 5. Ohyashiki K, Ohyashiki J-H, Hojo H, et al. Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage. Cancer. 1990;65:940-948[CrossRef][Medline] [Order article via Infotrieve].
6.
Tallman M-S, Neuberg D, Bennett J-M, et al.
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.
Blood.
2000;96:2405-2411 7. Lu G, Altman A-J, Benn P-A. Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several? Cancer Genet Cytogenet. 1993;67:81-89[CrossRef][Medline] [Order article via Infotrieve]. 8. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110:512-524[CrossRef][Medline] [Order article via Infotrieve].
9.
Carroll A, Civin C, Schneider N, et al.
The t(1;22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group study.
Blood.
1991;78:748-752
10.
Lion T, Haas O-A, Harbott J, et al.
The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children.
Blood.
1992;79:3325-3330 11. Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000;14:216-218[CrossRef][Medline] [Order article via Infotrieve]. 12. Arana Trejo R-M, Paredes Aguilera R, Nieto S, Kofman S. A t(1;22)(p13;q13) in four children with acute megakaryo-blastic leukemia (M7), two with Down syndrome. Cancer Genet Cytogenet. 2000;120:160-162[CrossRef][Medline] [Order article via Infotrieve].
13.
Mercher T, Busson-Le Coniat M, Monni R, et al.
Involvement of a human gene related to the Drosophilia spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia.
Proc Natl Acad Sci U S A.
2001;98:5776-5779 14. Ma Z, Morris SW, Valentine V, Li M, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1 ;22)(p13 ;q13) of acute megakaryoblastic leukemia. Nat Genet. 2001;28:220-221[CrossRef][Medline] [Order article via Infotrieve].
15.
Harris N-L-H, Jaffe E-S, Diebold J, et al.
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997.
J Clin Oncol.
1999;17:3835-3849 16. Garand R, Robillard N. Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. Hematol Cell Ther. 1996;38:471-486[CrossRef][Medline] [Order article via Infotrieve]. 17. Mitelman F. ISCN 1995. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995. 18. Aurich J, Dastugue N, Duchayne E, et al. Location of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic myeloid leukemia. Genes Chromosomes Cancer. 1997;20:148-154[CrossRef][Medline] [Order article via Infotrieve].
19.
Costello R, Sainty D, Lecine P, et al.
Detection of CBF
20.
Kong X-T, Ida K, Ichikawa H, et al.
Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript.
Blood.
1997;90:1192-1199 21. Mercher T, Busson-Le Coniat M, Khac FN, et al. Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7. Genes Chromosomes Cancer. 2002;33:22-28[CrossRef][Medline] [Order article via Infotrieve]. 22. Peto R, Peto J. Asymptotically efficient rank invariate test procedures. J Royal Stat Society. 1972;135:185-198. 23. Behar C, Bertrand Y, Rubie H, et al. Mitoxantrone and high dose Ara-C for the treatment of ANLL in childhood: a pilot study of the EORTC CLCG (EORTC 58872). Leukemia. 1992;6(suppl2):63-65. 24. Michel G, Leverger G, Leblanc T, et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant. 1996;17:191-196[Medline] [Order article via Infotrieve]. 25. Reiffers J, Stoppa A-M, Attal M, et al. for the BGMT group. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia. 1996;10:1874-1882[Medline] [Order article via Infotrieve]. 26. Haas O-A, Kronberger M, Mayerhofer L. Cytogenetic abnormalities associated with childhood acute myeloblastic leukemia. Recent Results Cancer Res. 1993;131:103-112[Medline] [Order article via Infotrieve]. 27. Martinez-Climent J-A. Molecular cytogenetics of childhood hematological malignancies. Leukemia. 1997;11:1999-2021[CrossRef][Medline] [Order article via Infotrieve].
28.
Raimondi S-C, Chang M-N, Ravindranah Y, et al.
for the Pediatric Oncology Group. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG 8821.
Blood.
1999;94:3707-3716 29. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 1995;9:1491-1498[Medline] [Order article via Infotrieve].
30.
Grimwade D, Walker H, Oliver F, et al.
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial.
Blood.
1998;92:2322-2333 31. Leverger G, Bernheim A, Daniel M-T, Flandrin G, Schaison G, Berger R. Cytogenetic study of 130 childhood acute nonlymphocytic leukemias. Med Pediatr Oncol. 1988;16:227-232[Medline] [Order article via Infotrieve]. 32. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;9:3323-3329. 33. Appelbaum F-R, Le Beau M-M, Willman C-L. Secondary leukemia. Washington, DC: American Society of Hematology, Education Program Book.; 1996:33-47.
34.
Grimwade D, Walker H, Harrison, et al.
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Blood.
2001;98:1312-1320 35. Nichols C-R, Roth B-J, Heerema N, Griep J, Tricot G. Hematologic neoplasia associated with primary mediastinal germ cell tumors. N Engl J Med. 1990;322:1425-1429[Abstract]. 36. Haas O-A, König M, Chudoba L, Sloziak M. FISH analysis of the first complex t(1;22)(p13;q22), a karyotype abnormality highly specific for infant acute megakaryoblastic leukemia (AML-M7). Cytogenet Cell Genet. 1999;85:71. 37. Jotterand Bellomo M, Parlier V, Mühlematter D, Grob J-P, Beris P. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet. 1992;59:138-160[CrossRef][Medline] [Order article via Infotrieve]. 38. Secker-Walker L-M, Mehta A, Bain B, on behalf of the UKCCG. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 1995;91:490-501[Medline] [Order article via Infotrieve] 39. De Oliviera J-S, Sale G-E, Bryant E-M, Sanders J, Buckner C-D. Acute megakaryoblastic leukemia in children: treatment with bone marrow transplantation. Bone Marrow Transplant. 1992;10:399-403[Medline] [Order article via Infotrieve]. 40. Imashuku S, Hibi S, Sako M, et al. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22). Cancer. 2000;88:1970-1975[CrossRef][Medline] [Order article via Infotrieve].
41.
Johansson B, Mertens F, Mitelman F.
Primary vs. secondary neoplasia-associated chromosomal abnormalities 42. Song W-J, Sullivan M-G, Legare R-D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166-175[CrossRef][Medline] [Order article via Infotrieve]. 43. Michaux L, Dierlamm J, Mecucci C, et al. Dicentric (1;15) in myeloid disorders. Cancer Genet Cytogenet. 1996;88:86-89[CrossRef][Medline] [Order article via Infotrieve]. 44. Smadja N, Krulik M, de Gramont A, Gonzalez-Canali G, Audebert A-A, Debray J. Refractory anemia with excess of blasts in transformation. Clinical, hematologic, and cytogenetic findings in nine patients. Cancer Genet Cytogenet. 1989;42:55-65[CrossRef][Medline] [Order article via Infotrieve]. 45. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol. 1991;47:17-27[Medline] [Order article via Infotrieve]. 46. Tsuchiya H, Kaneko Y, Seguchi S, Matsui Y, Matsuyama T, Matsuda I. Childhood myelodysplastic syndrome with clonal evolution progressing to acute megakaryoblastic leukemia (ANLL-M7). Cancer Genet Cytogenet. 1993;70:17-20[CrossRef][Medline] [Order article via Infotrieve]. 47. Vlasveld L-T, Splinter T-A-W, Hagemeijer A, Van Lom K, Löwenberg B. Acute myeloid leukaemia with +i(12p) shortly after treatment of mediastinal germ cell tumour. Br J Haematol. 1994;88:196-198[Medline] [Order article via Infotrieve]. 48. Zipursky A, Christensen H, De Harven E. Ultrastructural studies of the megakaryoblastic leukemias of Down syndrome. Leuk lymphoma. 1995;18:341-347[Medline] [Order article via Infotrieve].
The Appendix lists the name of the institute, with the center and number of cases in parentheses, followed by the names of other participants. Institut Paoli Calmettes (Marseille; n = 16): Jean Albert Gastaut, Didier Blaise, Christine Arnoulet, Danielle Sainty; CHU Toulouse (Toulouse; n = 9): Emilienne Kuhlein, Alain Robert, Françoise Huguet; Hôpital Debrousse (Lyon; n = 7): Anne Marie Manel, Claire Galambrun, Emmanuelle Homolle; Hôpital Necker (Paris; n = 4): Françoise Valensi, Pierre Quartier; CHU Nantes (Nantes; n = 3): Hervé Avet-Loiseau, Richard Garand, Françoise Mechinaud; Hôpital Robert Debré (Paris; n = 2): Etienne Vilmer; Hôpital Bicêtre (Paris; n = 2): Danielle Feneux, Anne Beauchamp-Nicoud; CHU Caen (Caen; n = 2): Michèle Malet, Patrick Boutard; Hôpital Haut Lévêque (Bordeaux; n = 1): Jean-Philippe Vial, Francis Lacombe, Jean-Michel Boiron, Philippe Bernard; Hôpital Universitaire de Genève (Genève, Suisse; n = 1): Pierre Wacker, Jacqueline Schmid; CHU La Timone (Marseille; n = 1): Chantal Fossat, Gerard Michel; CHU Reims (Reims) (n = 1): Sylvie Daliphard, Catherine Behar; CHU Brest (Brest; n = 1): Marie Chantal Leglise, Christian Berthou; CHU Dijon (Dijon; n = 1): Isabelle Luquet, Bernardine Favre, Marc Maynaide, Gérard Couillault; Hôpital Saint Antoine (Paris; n = 1): Mircea Adam, Judith Landman-Parker, Guy Leverger; and CHU Montpellier (Montpellier; n = 1): Jacques Taib, Geneviève Margueritte. Paola Ballerini (Hôpital Trousseau-Paris) and Florence Nguyen-Khac (Groupe Hospitalier Pitié-Salpétrière-Paris) performed the molecular analyses of OTT-MAL and FUS-ERG transcripts. Anna Aventin (Hopital San Pau-Barcelona) contributed to FISH studies.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Salek-Ardakani, G. Smooha, J. de Boer, N. J. Sebire, M. Morrow, L. Rainis, S. Lee, O. Williams, S. Izraeli, and H. J.M. Brady ERG Is a Megakaryocytic Oncogene Cancer Res., June 1, 2009; 69(11): 4665 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Malinge, S. Izraeli, and J. D. Crispino Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome Blood, March 19, 2009; 113(12): 2619 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Malinge, C. Ragu, V. Della-Valle, D. Pisani, S. N. Constantinescu, C. Perez, J.-L. Villeval, D. Reinhardt, J. Landman-Parker, L. Michaux, et al. Activating mutations in human acute megakaryoblastic leukemia Blood, November 15, 2008; 112(10): 4220 - 4226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Forestier, S. Izraeli, B. Beverloo, O. Haas, A. Pession, K. Michalova, B. Stark, C. J. Harrison, A. Teigler-Schlegel, and B. Johansson Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study Blood, February 1, 2008; 111(3): 1575 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-l. Gu, T. Mercher, J. W. Tyner, V. L. Goss, D. K. Walters, M. G. Cornejo, C. Reeves, L. Popova, K. Lee, M. C. Heinrich, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia Blood, July 1, 2007; 110(1): 323 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mercher, G. Wernig, S. A. Moore, R. L. Levine, T.-L. Gu, S. Frohling, D. Cullen, R. D. Polakiewicz, O. A. Bernard, T. J. Boggon, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model Blood, October 15, 2006; 108(8): 2770 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.C. T. Pipes, E. E. Creemers, and E. N. Olson The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes & Dev., June 15, 2006; 20(12): 1545 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bourquin, A. Subramanian, C. Langebrake, D. Reinhardt, O. Bernard, P. Ballerini, A. Baruchel, H. Cave, N. Dastugue, H. Hasle, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling PNAS, February 28, 2006; 103(9): 3339 - 3344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Jourdan, J.-M. Boiron, N. Dastugue, N. Vey, G. Marit, F. Rigal-Huguet, L. Molina, N. Fegueux, A. Pigneux, C. Recher, et al. Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience J. Clin. Oncol., October 20, 2005; 23(30): 7676 - 7684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rainis, T. Toki, J. E. Pimanda, E. Rosenthal, K. Machol, S. Strehl, B. Gottgens, E. Ito, and S. Izraeli The Proto-Oncogene ERG in Megakaryoblastic Leukemias Cancer Res., September 1, 2005; 65(17): 7596 - 7602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Garderet, M. Labopin, N.-C. Gorin, E. Polge, A. Baruchel, G. Meloni, J. Ortega, J. Vossen, D. Bunjes, G. Leverger, et al. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) Blood, January 1, 2005; 105(1): 405 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ahmed, A. Sternberg, G. Hall, A. Thomas, O. Smith, A. O'Marcaigh, R. Wynn, R. Stevens, M. Addison, D. King, et al. Natural history of GATA1 mutations in Down syndrome Blood, April 1, 2004; 103(7): 2480 - 2489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gurbuxani, P. Vyas, and J. D. Crispino Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome Blood, January 15, 2004; 103(2): 399 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rainis, D. Bercovich, S. Strehl, A. Teigler-Schlegel, B. Stark, J. Trka, N. Amariglio, A. Biondi, I. Muler, G. Rechavi, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21 Blood, August 1, 2003; 102(3): 981 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Hitzler, J. Cheung, Y. Li, S. W. Scherer, and A. Zipursky GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome Blood, June 1, 2003; 101(11): 4301 - 4304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nimer, D. MacGrogan, S. Jhanwar, S. Alvarez, N. Dastugue, and R. Berger Chromosome 19 abnormalities are commonly seen in AML, M7 Blood, November 15, 2002; 100(10): 3838 - 3838. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
5/del(5q) or 
3 unrelated abnormalities). The percentage of simple
karyotypes (1 or 2 unrelated abnormalities) was higher in children
(61.5%) than in adults (41.5%). The degree of complexity was
lower in children than in adults (< 5 changes in most children and
> 5 changes in most adults).
-fetoprotein in both cases, neuron specific enolase in one and
balanced rearrangements vs. genomic imbalances?
Genes Chromosomes Cancer.
1996;16:155-163